Is Sppi a good investment?
Table of Contents
Is Sppi a good investment?
Spectrum Pharmaceuticals has received a consensus rating of Buy. The company’s average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Will Sppi go back up?
The Wall Street analyst predicted that Spectrum Pharmaceuticals’s share price could reach $4.00 by Mar 21, 2023. The average Spectrum Pharmaceuticals stock price prediction forecasts a potential upside of 419.48% from the current SPPI share price of $0.77.
Did Sppi get FDA approval?
–(BUSINESS WIRE)– Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced today that the U.S. Food and Drug Administration (FDA) has granted Accelerated Approval of Beleodaq™ for the …
Why is SPPI stock falling?
The big decline came after the company announced that the U.S. Food and Drug Administration turned down approval of Rolontis in treating neutropenia in patients receiving cancer drugs that decrease bone marrow activity.
Is Spectrum a good stock to buy?
Spectrum Brands has received a consensus rating of Buy. The company’s average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.
What is Rolontis?
Rolontis (eflapegrastim) is an investigational granulocyte-colony stimulating factor (G-CSF) analog in development as a treatment for chemotherapy-induced neutropenia.
Did Rolontis get approved?
The FDA turned down Rolontis’ application to treat neutropenia in cancer patients on myelosuppressive therapies. In a complete response letter, the FDA raised issues with manufacturing “deficiencies” and flagged the need for a site reinspection, Spectrum said in a release.
Who owns SPPI stock?
Top 10 Owners of Spectrum Pharmaceuticals Inc
| Stockholder | Stake | Shares owned |
|---|---|---|
| BlackRock Fund Advisors | 7.12% | 12,817,131 |
| D. E. Shaw & Co. LP | 4.36% | 7,845,726 |
| The Vanguard Group, Inc. | 4.25% | 7,646,403 |
| SSgA Funds Management, Inc. | 1.85% | 3,338,316 |
Is Poziotinib FDA approved?
FDA Accepts New Drug Application for Poziotinib in HER2 Exon 20+ NSCLC. A new drug application has been accepted by the FDA for poziotinib in patients with advanced or metastatic non–small cell lung cancer with HER2 exon 20 insertion mutations.
